Put Spread on CLVS on 1/17/2018

Clovis Oncology, Inc. (CLVS) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets.

The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3.

Shares have fallen through a "support" and lower share prices are expected for this stock.

52-Weeks Tradiing Range: $45.42 - 99.45

Entry Point: $55.41

Trade Buy 1 February $60.00 Put at $7.00 Sell 1 February $50.00 Put at $1.50 For a net debit of $5.50 Profit/Loss Analysis Breakeven at $54.50 Maximum profit is $450.00 at strike of $50.00 Maximum loss is ($550.00) at strike of $60.00 Closing Summary Sold 1 February $60.00 Put at $11.50 Bought 1 February $50.00 Put at $2.00

Position closed on 2/9/2018 at price of $9.50 with a 72.73% gain in 23 days.

Updates

2/9/2018 10:03:02 AM

We are taking profits on CLVS Put Spread

Back to Portfolio